Notably, ICIs targeting PD‐1 (programmed cell death protein 1), PD‐L1 (programmed death‐ligand 1), and CTLA‐4 (cytotoxic T‐lymphocyte‐associated protein 4) in conjunction with personalized cancer vaccines has shown promising results. Here, PDCD1 is linked to cancer.